Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab for Recurrent HCC After Liver Transplantation
NCT04564313Phase 1Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04564313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564313.